Table 1.

Short-term methotrexate treatment does not result in generalized immunosuppression.

Number of r-hαGAL treatments	r-hαGAL-specific IgG titres
	0 mg/kg methotrexate	50 mg/kg methotrexate
8	6201 ± 2125*	626 ± 299
Number of r-hGAA treatments	r-hGAA-specific IgG titres
0 mg/kg methotrexate	50 mg/kg methotrexate
2 (post 16th r-hαGAL)	8456 ± 5780	9412 ± 3204

Groups of five Fabry mice were given 8 biweekly i.v. injections (3 mg/kg r-h αGAL). For the first 6 weeks mice received MTX (i.v., 10 mg/kg) or vehicle 48 h after each r-h αGAL injection (three administrations of MTX or vehicle). For the last 4 weeks the same mice were also injected i.p. with an irrelevant enzyme (1 mg/kg r-hGAA). Serum samples were collected at weeks 17 and 37 and were analysed for GAA-specific IgG or αGAL-specific IgG by ELISA. Results shown represent mean and standard error of end-point titres.

^*P < 0·05 compared to MTX group.